CY1122827T1 - Παροχη χοληστερυλεστερα σε στεροειδογονους ιστους - Google Patents

Παροχη χοληστερυλεστερα σε στεροειδογονους ιστους

Info

Publication number
CY1122827T1
CY1122827T1 CY20201100021T CY201100021T CY1122827T1 CY 1122827 T1 CY1122827 T1 CY 1122827T1 CY 20201100021 T CY20201100021 T CY 20201100021T CY 201100021 T CY201100021 T CY 201100021T CY 1122827 T1 CY1122827 T1 CY 1122827T1
Authority
CY
Cyprus
Prior art keywords
cholesteryl ester
tissues
steroidated
delivery
organ
Prior art date
Application number
CY20201100021T
Other languages
English (en)
Inventor
Bruce. J. AUERBACH
Reynold Homan
Brian Krause
Original Assignee
Alphacore Pharma Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alphacore Pharma Llc filed Critical Alphacore Pharma Llc
Publication of CY1122827T1 publication Critical patent/CY1122827T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y203/00—Acyltransferases (2.3)
    • C12Y203/01—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • C12Y203/01043—Phosphatidylcholine-sterol O-acyltransferase (2.3.1.43), i.e. lecithin-cholesterol acyltransferase or LCAT

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Αποκαλύπτονται συνθέσεις και μέθοδοι για την θεραπευτική αντιμετώπιση καταστάσεων που χαρακτηρίζονται από χαμηλή HDL-CE, η οποία μπορεί να οδηγήσει σε μειωμένη απελευθέρωση χοληστερυλεστέρα σε στεροειδογόνους ιστούς, μειώνοντας την ικανότητα του οργάνου να παράγει στεροειδή ειδικά κατά τη διάρκεια περιόδων ζήτησης, στρες ή συνδρόμου συστηματικής φλεγμονώδους απόκρισης.
CY20201100021T 2010-05-06 2020-01-09 Παροχη χοληστερυλεστερα σε στεροειδογονους ιστους CY1122827T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33190910P 2010-05-06 2010-05-06
PCT/US2011/035500 WO2011140429A1 (en) 2010-05-06 2011-05-06 Delivery of cholesteryl ester to steroidogenic tissues

Publications (1)

Publication Number Publication Date
CY1122827T1 true CY1122827T1 (el) 2021-05-05

Family

ID=44121177

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20201100021T CY1122827T1 (el) 2010-05-06 2020-01-09 Παροχη χοληστερυλεστερα σε στεροειδογονους ιστους

Country Status (22)

Country Link
US (2) US20130045194A1 (el)
EP (1) EP2566505B1 (el)
JP (1) JP6174995B2 (el)
CN (1) CN103025348B (el)
AU (1) AU2011247985B2 (el)
BR (1) BR112012028462A2 (el)
CA (1) CA2797126C (el)
CY (1) CY1122827T1 (el)
DK (1) DK2566505T3 (el)
ES (1) ES2764733T3 (el)
HR (1) HRP20200008T1 (el)
HU (1) HUE047288T2 (el)
LT (1) LT2566505T (el)
ME (1) ME03682B (el)
MX (1) MX336872B (el)
NZ (1) NZ603453A (el)
PL (1) PL2566505T3 (el)
PT (1) PT2566505T (el)
RS (1) RS59867B1 (el)
RU (1) RU2012152320A (el)
SI (1) SI2566505T1 (el)
WO (1) WO2011140429A1 (el)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2853259A1 (en) * 2013-09-30 2015-04-01 Université Pierre et Marie Curie (Paris 6) Reconstituted high density lipoproteins composition and uses thereof
KR20200085292A (ko) * 2017-11-07 2020-07-14 알파코어 파마 엘엘씨 심장 질병, 심혈관 질병 및 관련 질환 및 증상을 치료하고 그로부터 보호하는 방법

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0910343A1 (en) * 1996-07-03 1999-04-28 University Of Pittsburgh Emulsion formulations for hydrophilic active agents
US6498019B1 (en) * 1997-04-11 2002-12-24 Takeda Chemical Industries, Ltd. Lecithin-cholesterol acyltransferase protein
DE60222670T3 (de) * 2001-07-27 2011-08-18 N.V. Nutricia Orale zusammesetzung zur vorbeugung oder behandlung von sepsis
IL158554A0 (en) * 2003-10-22 2004-05-12 Enzymotec Ltd Mimetic lipids as dietary supplements
BRPI0508966A (pt) 2004-03-26 2007-08-21 Lilly Co Eli composto, composição farmacêutica, e, uso de um composto
EP2037928B1 (en) 2006-06-26 2012-01-11 Amgen Inc. Methods for treating atherosclerosis
EP2489730B1 (en) * 2007-07-26 2015-12-30 Amgen, Inc Modified lecithin-cholesterol acyltransferase enzymes
WO2009124055A1 (en) * 2008-03-31 2009-10-08 University Of Chicago Human apoa-i mutants
AU2010259875B2 (en) * 2009-06-12 2015-10-22 Alphacore Pharma Llc Use of LCAT for treating anemia and red blood cell dysfunction

Also Published As

Publication number Publication date
SI2566505T1 (sl) 2020-03-31
ME03682B (me) 2021-01-20
AU2011247985B2 (en) 2015-12-03
LT2566505T (lt) 2020-02-10
CA2797126A1 (en) 2011-11-10
JP2013528594A (ja) 2013-07-11
US20130045194A1 (en) 2013-02-21
PL2566505T3 (pl) 2020-06-29
BR112012028462A2 (pt) 2016-07-19
PT2566505T (pt) 2020-01-15
DK2566505T3 (da) 2020-01-20
CN103025348A (zh) 2013-04-03
US20150190479A1 (en) 2015-07-09
MX2012012711A (es) 2012-11-21
ES2764733T3 (es) 2020-06-04
EP2566505B1 (en) 2019-10-16
WO2011140429A1 (en) 2011-11-10
RU2012152320A (ru) 2014-06-20
NZ603453A (en) 2014-12-24
AU2011247985A1 (en) 2012-11-29
HRP20200008T1 (hr) 2020-03-20
RS59867B1 (sr) 2020-03-31
CA2797126C (en) 2020-06-02
CN103025348B (zh) 2015-09-02
JP6174995B2 (ja) 2017-08-02
EP2566505A1 (en) 2013-03-13
HUE047288T2 (hu) 2020-04-28
MX336872B (es) 2016-02-04

Similar Documents

Publication Publication Date Title
CY1122909T1 (el) Μεθοδοι αντιμετωπισης της ηωσινοφιλικης οισοφαγιτιδας με χορηγηση αναστολεα του ιl-4r
CY1121150T1 (el) Νευροδραστικα 19-αλκοξυ-17-υποκατεστημενα στεροειδη, χρησιμα σε μεθοδους θεραπειας
EA201391602A1 (ru) Контролируемое высвобождение иммунодепрессантов из синтетических наноносителей
CY1119166T1 (el) Θεραπευτικες συνθεσεις νουκλεασης και μεθοδοι
CY1121742T1 (el) Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων
CR20170070A (es) Composición, método y preparación del ácido biliar sintético
AU2016204344A1 (en) Improved methods and compositions for wound healing
CY1125114T1 (el) Συνθεσεις και μεθοδοι για τη μειωση μειζωνων ανεπιθυμητων καρδιαγγειακων συμβαντων
EA201290497A1 (ru) Терапевтические полимерные наночастицы, включающие кортикостероиды, и способы получения таковых
PH12014502445A1 (en) Targeted modification of malate dehydrogenase
MX346224B (es) Composiciones y metodos para el tratamiento de inflamacion cronica y enfermedades inflamatorias.
BR112013003216A2 (pt) composições sintéticas de ácido biliar e métodos
BR112013008881A2 (pt) métodos e composições para tratamento de hemofilia b
WO2012020308A3 (en) Pancreatic duct progenitor cells and microrna obtained therefrom for use in tissue regeneration
MX2013009175A (es) Composiciones que comprenden acido peroxi alfa-cetocarboxilico y metodos para producirlas y usarlas.
EP2638159A4 (en) COMPOSITIONS, KITS AND METHODS FOR TREATING CARDIOVASCULAR, IMMUNOLOGICAL AND INFLAMMATORY DISEASES
MX2020009699A (es) Fenil acetato de l-ornitina y metodos para elaborar el mismo.
EP4234698A3 (en) Compositions and methods of use for therapeutic low density lipoprotein-related protein 6 (lrp6) antibodies
CY1117654T1 (el) Πολυαιθυλενογλυκολιωμενη απελινη και χρησεις αυτης
EP3634437A4 (en) COMPOSITIONS AND PROCEDURES FOR EX VIVO EXPANSION OF NATURAL KILLER CELLS AND THEIR THERAPEUTIC USES
CA2868551C (en) Methods and compositions for treating inflammation
EA201990438A1 (ru) Композиции, содержащие 5-холестен-3,25-диол, 3-сульфат (25hc3s) или его фармацевтически приемлемую соль и по меньшей мере один циклический олигосахарид, и способы их применения
CY1122827T1 (el) Παροχη χοληστερυλεστερα σε στεροειδογονους ιστους
BR112014009376A2 (pt) composições
CY1123202T1 (el) Σκευασμα υδροκορτιζονης ελεγχομενης απελευθερωσης